We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $160M
1-Year Est. Return 517.12%
This Fund
S&P 500
This Quarter Est. Return
+26.12%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$108M
AUM Growth
-$9.62M
Cap. Flow
-$11.4M
Cap. Flow %
-10.58%
Top 10 Hldgs %
65.66%
Holding
39
New
8
Increased
9
Reduced
4
Closed
8

Top Buys

Rank Stock Value
1
ALIM
Alimera Sciences
ALIM
+$3.22M
2
IMGN
Immunogen Inc
IMGN
+$2.24M
3
ANNX icon
Annexon
ANNX
+$1.57M
4
NSPR icon
InspireMD
NSPR
+$1.44M
5
GERN icon
Geron
GERN
+$1.36M

Top Sells

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$9.89M
2
ADMA icon
ADMA Biologics
ADMA
+$4.72M
3
LNTH icon
Lantheus
LNTH
+$4.49M
4
TERN
Terns Pharmaceuticals
TERN
+$1.42M
5
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$1.33M

Sector Composition

Rank Sector Weight
1 Healthcare 98.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JSPR icon
1
Jasper Therapeutics
JSPR
$23.6M
$14.8M 13.79%
1,121,904
– –
ADMA icon
2
ADMA Biologics
ADMA
$2.22B
$10.1M 9.34%
2,726,051
-1,273,949
-32% -$4.72M
LNTH icon
3
Lantheus
LNTH
$6.59B
$8.39M 7.79%
100,000
-50,000
-33% -$4.49M
TELA icon
4
TELA Bio
TELA
$38.9M
$7.56M 7.02%
746,087
– –
PRAX icon
5
Praxis Precision Medicines
PRAX
$10.1B
$5.96M 5.54%
345,667
– –
HRTX icon
6
Heron Therapeutics
HRTX
$92.9M
$5.22M 4.85%
4,500,000
– –
QIPT
7
DELISTED
Quipt Home Medical
QIPT
$5.18M 4.81%
970,000
+170,000
+21% +$1M
ALIM
8
DELISTED
Alimera Sciences
ALIM
$4.85M 4.5%
1,659,654
+1,401,901
+544% +$3.22M
OPTN
9
DELISTED
OptiNose
OPTN
$4.42M 4.11%
239,791
+6,667
+3% +$158K
THC icon
10
Tenet Healthcare
THC
$21.1B
$4.22M 3.92%
51,900
– –
IMGN
11
DELISTED
Immunogen Inc
IMGN
$3.58M 3.32%
+189,500
New +$2.24M
CABA icon
12
Cabaletta Bio
CABA
$455M
$3.23M 3%
250,000
– –
GRTX
13
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$3.12M 2.9%
1,000,000
– –
PNT
14
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$3.11M 2.88%
342,936
-151,200
-31% -$1.33M
MLTX icon
15
MoonLake Immunotherapeutics
MLTX
$1.55B
$2.82M 2.62%
55,300
+31,900
+136% +$858K
GERN icon
16
Geron
GERN
$949M
$2.5M 2.32%
778,500
+478,500
+160% +$1.36M
NSPR icon
17
InspireMD
NSPR
$34.7M
$2.27M 2.11%
+904,029
New +$1.44M
CTLT
18
DELISTED
CATALENT, INC.
CTLT
$2.17M 2.01%
50,000
– –
ETNB
19
DELISTED
89bio
ETNB
$1.8M 1.67%
95,000
-3,500
-4% -$61.5K
IOVA icon
20
Iovance Biotherapeutics
IOVA
$2.87B
$1.69M 1.57%
240,000
+20,000
+9% +$143K
AVDL
21
DELISTED
Avadel Pharmaceuticals
AVDL
$1.65M 1.53%
100,000
+74,257
+288% +$965K
ANNX icon
22
Annexon
ANNX
$886M
$1.62M 1.5%
459,746
+359,746
+360% +$1.57M
ICVX
23
DELISTED
Icosavax, Inc. Common Stock
ICVX
$1.6M 1.48%
160,630
+10,630
+7% +$85.1K
EDSA icon
24
Edesa Biotech
EDSA
$50.8M
$1.04M 0.97%
183,088
– –
IFRX icon
25
InflaRx
IFRX
$271M
$892K 0.83%
+200,000
New +$895K
1
2

Similar funds

BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM
RFS
Richardson Financial Services Medway, Massachusetts $160M AUM 16.71% 1-Year Est. Return
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
LCA
Legend Capital Advisors New York $160M AUM
SA
swisspartners Advisors Zurich, Switzerland $159M AUM 36.51% 1-Year Est. Return
SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
CF
CBM Financial Austin, Texas $160M AUM

Velan Capital Investment Management's Q2 2023 Portfolio in Review

As of Q2 2023, Velan Capital Investment Management held 39 positions worth $108M, down 8.2% from $117M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Velan Capital Investment Management withdrew a net $11.4M in Q2 2023, closing 8 positions and reducing 4 holdings. Its most notable exit was Immunocore, an estimated $9.89M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier.

Against the trend, Velan Capital Investment Management opened a new position in Immunogen Inc worth $3.58M.

  • Velan Capital Investment Management's largest Q2 2023 buy was Immunogen Inc: 189,500 shares worth $3.58M.
  • Velan Capital Investment Management added most to Alimera Sciences in Q2 2023, an estimated $3.22M increase.
  • Velan Capital Investment Management's biggest Q2 2023 reduction was ADMA Biologics, cutting an estimated $4.72M.
  • Velan Capital Investment Management fully exited Immunocore in Q2 2023, selling an estimated $9.89M.
  • Velan Capital Investment Management's ten largest holdings make up 66% of its $108M portfolio in Q2 2023.
  • Velan Capital Investment Management opened 8 new positions and closed 8 in Q2 2023.
  • Velan Capital Investment Management's portfolio value fell 8.2% quarter-over-quarter to $108M.

Based on Velan Capital Investment Management's 13F filing for Q2 2023, filed 11 Aug 2023.